Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products, and animal health products in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. This segment's primary products include Atropine Sulfate Ophthalmic Solution; Clobetasol Propionate Cream And Ointment; Ephedrine Sulfate Injection; Lidocaine Ointment; Methylene Blue Injection; Myorisan soft gelatin capsules; Nembutal sodium solution; Phenylephrine Hydrochloride Ophthalmic Solution; and Zioptan tafluprost ophthalmic solution. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
http://www.priceseries.com/trade/AKRX-Akorn-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2018060520180712.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments